drugset / Trial / NCT06463132

Phase 1b Clinical Trial to Evaluate PEP and EUFLEXXA for Knee Osteoarthritis (KOA)

NCT06463132

RandomizedParallel-groupOpen-labelTreatment

Summary

Evaluate the safety and exploratory efficacy of single intra-articular injections of PEP reconstituted with 0.9% Normal Saline at a low dose (one vial PEP) and high dose (two vials PEP), with and without EUFLEXXA, for the treatment of Knee Osteoarthritis

Timeline

Start
2024-11-01
Primary completion
2025-11-01
Completion
2025-11-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Hyaluronic Acid Other / unclassified Other
Subject PEP Other / unclassified Other
Subject PEP Other / unclassified Other

Indications